Clinical trial · Interventional
A Study on the Angioarchitecture of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor patient accrual
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) is one of the commonest solid malignancies in Hong Kong as well as globally. Transarterial therapy has been playing an important role in the treatment algorithm for patients with HCC. The primary purpose of transarterial therapy is eradication of the viability of the targeted tumors. The treatment outcomes have been variable among the various treatments, in general, there is still much room for improvement, especially for large size tumors. From the studies on Transarterial chemoembolization (TACE), it is known that the treatment outcome is affected by the nature and the formulation of therapeutic agents that are delivered, which is related to the angioarchitecture of the tumor. Knowledge on the angioarchitecture of HCC is essential for the understanding of the requirements for effective transarterial treatment of HCC. This prospective study is aimed to study the angioarchitecture of HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| embolization | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Tumor <=3cm
- description
- Embolization with particulate or liquid embolic agent
- interventionNames
- Other: embolization
- type
- OTHER
- label
- Tumor >3cm to 7cm
- description
- Embolization with particulate or liquid embolic agent
- interventionNames
- Other: embolization
- type
- OTHER
- label
- Tumor > 7cm
- description
- Embolization with particulate or liquid embolic agent
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age above 18 years 2. HCC suitable for partial hepatectomy 3. Child-Pugh A or B cirrhosis 4. Eastern Cooperative Oncology Group performance score 0 or 1 5. Barcelona clinic liver cancer (BCLC) staging A or B 6. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology 7. Massive expansive tumor morphology with measurable lesion on CT (characterized by well-defined spherical or globular configuration, with or without tumor capsule or satellite lesions) Exclusion Criteria: 1. Previous treatment with liver resection, ablation, chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy), 2. Evidence of tumor invasion of portal vein or hepatic vein 3. History of acute tumor rupture presenting with hemo-peritoneum 4. Infiltrative tumor morphology (characterized by ill- defined tumor margin and amorphous configuration) or diffuse tumor morphology (characterized by large number of small nodules) 5. Serum creatinine level \> 150umol/L
References
Publications (0)
Data not yet available